Access To Medicine Foundation
  • Who we are
  • What we do
  • Impact
  • Insights & resources
  • News & events
  • Donate
Donate

Who we are

An independent non-profit organisation accelerating progress toward global health equity.

  • About us
  • How we drive change
  • Our strategy 2022 - 2026
  • Governance
  • Team
  • Funders
  • Annual reports

What we do

We catalyse progress toward equitable access to essential medicines in low- and middle-income countries through our work across diverse research areas.

  • R&D-based pharma companies
  • Medical gas companies
  • Generic medicine manufacturers
  • Diagnostics companies
  • Vaccine manufacturers
  • Antimicrobial resistance
  • Diabetes care

Impact

Discover how our work drives real-world progress on access to medicine.

  • Our achievements
  • Voices of our community
  • How we drive change
  • Partner with us

Insights & resources

Discover our evidence-based research, insights and other changemaking tools.

  • Research hub
  • Company profiles & report cards
  • Access insights
  • The Health Equity podcast
  • Health Equity through Her Lens

News & events

Stay informed on our latest events, collaborations, engagements, and Foundation news.

  • News
  • Events & engagements
  • In the media

Follow us

Often searched

Index ranking

Vacancies

10 year analysis

Follow us

  • About us
  • How we drive change
  • Our strategy 2022 - 2026
  • Governance
  • Team
  • Funders
  • Annual reports
  • R&D-based pharma companies
  • Medical gas companies
  • Generic medicine manufacturers
  • Diagnostics companies
  • Vaccine manufacturers
  • Antimicrobial resistance
  • Diabetes care
  • Our achievements
  • Voices of our community
  • How we drive change
  • Partner with us
  • Research hub
  • Company profiles & report cards
  • Access insights
  • The Health Equity podcast
  • Health Equity through Her Lens
  • News
  • Events & engagements
  • In the media

Date

14 March 2022

Project Syndicate op-ed: Insulin Belongs to the World

In an op-ed published by Project Syndicate, Access to Medicine Foundation CEO Jayasree K. Iyer argues that governments and pharmaceutical companies must do their part to increase access to insulin in low- and middle-income countries – including not just older forms of human insulin, but also the innovative analog insulins which are increasingly becoming the preferred choice of both diabetes patients and doctors.

Direct links

Read the full article

When insulin was discovered 101 years ago, scientists involved said they wanted to make insulin as widely available as possible because “it belongs to the world.” But as Jayasree points out, this ambition will not be fulfilled until every person who needs insulin – whether they have Type 1 or Type 2 diabetes – is assured reliable access to an affordable supply of the treatments that suit them best. 

To reach this goal, chronic problems in the insulin market must be addressed, as explored in the article.

Project Syndicate, known as "the world's opinion page", is a New York-based international media organisation that publishes commentary and analysis on a variety of important topics, and also syndicates these opinion pieces to print publications around the world.

Access to Medicine Foundation

Subscribe to our newsletter

Vacancies FAQs Contact us

Follow us

Access to Medicine Foundation is funded by

Terms & conditions Privacy & cookie policy Disclaimer

Copyright 2004 - 2026 Access to Medicine Foundation - All Rights Reserved